Patents Assigned to NoNO Inc.
-
Patent number: 10064910Abstract: The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment invoices administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g. by administration of tPA). Administration a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered.Type: GrantFiled: June 23, 2012Date of Patent: September 4, 2018Assignee: NoNO Inc.Inventor: Michael Tymianski
-
Patent number: 10046060Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: GrantFiled: August 24, 2016Date of Patent: August 14, 2018Assignee: NoNO INC.Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
-
Patent number: 9629892Abstract: The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).Type: GrantFiled: August 12, 2011Date of Patent: April 25, 2017Assignee: NoNO Inc.Inventors: Michael Tymianski, Peter S. Lu, Jonathan David Garman
-
Patent number: 9610323Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.Type: GrantFiled: January 14, 2015Date of Patent: April 4, 2017Assignee: NoNO INC.Inventors: Michael Tymianski, Jonathan David Garman
-
Patent number: 9566284Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.Type: GrantFiled: November 26, 2013Date of Patent: February 14, 2017Assignee: NONO Inc.Inventors: Xiujun Sun, Michael Tymianski, Jonathan David Garman
-
Patent number: 9433685Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: GrantFiled: December 29, 2014Date of Patent: September 6, 2016Assignee: NONO INC.Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
-
Patent number: 9365620Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: May 9, 2014Date of Patent: June 14, 2016Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 9334256Abstract: This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.Type: GrantFiled: June 15, 2012Date of Patent: May 10, 2016Assignee: NoNO INC.Inventors: Xiujun Sun, Michael Tymianski
-
Patent number: 9241970Abstract: The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.Type: GrantFiled: February 22, 2013Date of Patent: January 26, 2016Assignee: NoNO Inc.Inventor: Michael Tymianski
-
Patent number: 9161965Abstract: The invention provides methods of treating a patient having epilepsy in which an effective regime of an agent that inhibits specific binding of PSD-95 to an NMDA receptor is administered to a patient.Type: GrantFiled: May 14, 2009Date of Patent: October 20, 2015Assignee: NoNO Inc.Inventors: James Gurd, Crystal Dykstra, Michael Tymianski
-
Publication number: 20150202253Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.Type: ApplicationFiled: January 14, 2015Publication date: July 23, 2015Applicant: NoNO Inc.Inventors: Michael Tymianski, Jonathan David Garman
-
Patent number: 9073976Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.Type: GrantFiled: March 15, 2013Date of Patent: July 7, 2015Assignee: NoNO Inc.Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
-
Patent number: 9061070Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: GrantFiled: September 14, 2012Date of Patent: June 23, 2015Assignee: NoNO, Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20150126460Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: ApplicationFiled: December 29, 2014Publication date: May 7, 2015Applicant: NoNO Inc.Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
-
Patent number: 8940699Abstract: The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.Type: GrantFiled: June 10, 2010Date of Patent: January 27, 2015Assignee: NoNO Inc.Inventors: Michael Tymianski, Jonathan David Garman
-
Patent number: 8933013Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: GrantFiled: June 10, 2010Date of Patent: January 13, 2015Assignee: NoNO Inc.Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
-
Publication number: 20140323406Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemi by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.Type: ApplicationFiled: February 7, 2014Publication date: October 30, 2014Applicant: NONO INC.Inventor: Michael Tymianksi
-
Publication number: 20140274906Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: NoNO Inc.Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
-
Publication number: 20140235619Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.Type: ApplicationFiled: November 26, 2013Publication date: August 21, 2014Applicant: NONO INC.Inventors: Xiujun Sun, Michael Tymianski, David Garman
-
Publication number: 20140162957Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.Type: ApplicationFiled: November 26, 2013Publication date: June 12, 2014Applicant: NoNO Inc.Inventor: Jonathan David Garman